|Description||GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.|
|Synonyms||tert-butyl ((R)-1-((S)-2-(((S)-5-guanidino-1-oxopentan-2-yl)carbamoyl)pyrrolidin-1-yl)-1-oxo-3-phenylpropan-2-yl)carbamate hemisulfate; LY 178207; Boc-D-Phe-Pro-Arg-H;69201-89-4 (free base)|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator IVAX Drug Research Institute|
Dabigatran etexilate mesylate
Dabigatran etexilate mesylate is the orally active prodrug of dabigatran. It is a reversible and selective, direct thrombin inhibitor (DTI).
GYKI-14451 is a synthetic tripeptide inhibitor of thrombin.It has anti-atherosclerotic activity.
Eltrombopag is a is an agonist of the c-mpl (TpoR) receptor used as treatment for thrombocytopenia.It has been developed for certain conditions that lead to thr...
Ximelagatran, an ester prodrug of melagatran, with anticoagulant effect, is the first member of direct thrombin inhibitors that can be taken orally.
H-D-Phe-Pro-arginal is a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. It has a similar efficacy ...
GYKI14451 is a synthetic tripeptide inhibitor of thrombin. It has anti-atherosclerotic activity.
Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.
Argatroban is an anticoagulant that is a direct thrombin inhibitor. Argatroban was approved in 2000 for prophylaxis or treatment of thrombosis in patients with ...
AEBSF is a water soluble, irreversible serine protease inhibitor; inhibits proteases like chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
Dabigatran etexilate(BIBR-1048) is the orally active prodrug of dabigatran; Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) with Ki va...
Efegatran is a thrombin inhibitor under the development of Eli Lilly. It can be used for the treatment of thromboembolic disorders. No development reported was ...
Dabigatran is a very potent anticoagulant， shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of...
Flovagatran is a thrombin inhibitor originated by Trigen Holdings AG. In Dec 2010, Phase-II for Thrombosis was discontinued.
Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding ...
Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant. Research for th...
VE-1902 is a novel and selective inhibitor of thrombin. Study in vivo and in vitro showed that VE-1902 inhibits thrombin via binding to it reversibly.
Dabigatran ethyl ester
Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran provides a stable anticoagulation effect w...
SFLLRNPNDKYEPF is a synthetic thrombin receptor agonist peptide and causes platelet aggregation (EC50 = 4 μM) and secretion .